{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:34:54Z","timestamp":1780511694866,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ekir.2024.04.058","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T02:21:21Z","timestamp":1714789281000},"page":"2260-2268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Cell-Based Assay to Measure the Activity of the Complement Convertases"],"prefix":"10.1016","volume":"9","author":[{"given":"Ma\u0142gorzata","family":"Stasi\u0142oj\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Stasi\u0142oj\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Ku\u017aniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodriguez de C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-2301","authenticated-orcid":false,"given":"Marcin","family":"Okr\u00f3j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.04.058_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2024.04.058_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system Part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ki.2012.250","article-title":"Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation","volume":"82","author":"Paixao-Cavalcante","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.058_bib5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.058_bib6","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","article-title":"A\u00a0prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function","volume":"119","author":"Roumenina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.058_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2024.04.058_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molimm.2020.10.015","article-title":"Complement-mediated kidney diseases","volume":"128","author":"Poppelaars","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.058_bib10","doi-asserted-by":"crossref","first-page":"18960","DOI":"10.1074\/jbc.M609636200","article-title":"Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism","volume":"282","author":"Herbert","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2024.04.058_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/imr.13137","article-title":"The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: from a pathogenic mechanism to a therapeutic target","volume":"313","author":"Risitano","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2024.04.058_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697313","article-title":"Expanding horizons in complement analysis and quality control","volume":"12","author":"Frazer-Abel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/imr.13131","article-title":"Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases","volume":"313","author":"Rodriguez de Cordoba","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2024.04.058_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex\u00a0vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00262-019-02304-0","article-title":"Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics","volume":"68","author":"Felberg","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ekir.2024.04.058_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.02.014","article-title":"Gain-of-function mutation in complement C2 protein identified in a patient with aHUS","volume":"146","author":"Urban","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/cancers14051270","article-title":"In silico designed gain-of-function variants of complement C2 support cytocidal activity of anticancer monoclonal antibodies","volume":"14","author":"Urban","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ekir.2024.04.058_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112675","article-title":"Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies","volume":"476","author":"Stasilojc","year":"2020","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.ekir.2024.04.058_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s12032-013-0759-5","article-title":"Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement","volume":"30","author":"Okroj","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.ekir.2024.04.058_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A\u00a0novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4049\/jimmunol.174.4.2084","article-title":"Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata","volume":"174","author":"Nunn","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"Roth","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.058_bib23","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.4049\/jimmunol.162.5.2906","article-title":"Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding","volume":"162","author":"Hourcade","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.724361","article-title":"Gain-of-function mutations R249C and S250C in complement C2 protein increase C3 deposition in the presence of C-reactive protein","volume":"12","author":"Urban","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010049","article-title":"The acquisition of complement-dependent cytotoxicity by the Type II anti-CD20 therapeutic antibody obinutuzumab","volume":"16","author":"Kuzniewska","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ekir.2024.04.058_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047245","article-title":"Functional analyses of complement convertases using C3 and C5-depleted sera","volume":"7","author":"Okroj","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.04.058_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2015.03.248","article-title":"The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome","volume":"66","author":"Martinez-Barricarte","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib28","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1074\/jbc.M211579200","article-title":"Functional activity of the complement regulator encoded by Kaposi\u2019s sarcoma-associated herpesvirus","volume":"278","author":"Spiller","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2024.04.058_bib29","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1074\/jbc.M410179200","article-title":"Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)","volume":"280","author":"Harris","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2024.04.058_bib30","doi-asserted-by":"crossref","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","article-title":"Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis","volume":"290","author":"Vasilev","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2024.04.058_bib31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fimmu.2018.01691","article-title":"Functional characterization of alternative and classical pathway C3\/C5 convertase activity and inhibition using purified models","volume":"9","author":"Zwarthoff","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-1759(82)90386-6","article-title":"A\u00a0new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes","volume":"51","author":"Rother","year":"1982","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.ekir.2024.04.058_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.058_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/imr.13164","article-title":"Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi-protein cascade of the complement system","volume":"313","author":"Schmidt","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2024.04.058_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584509","article-title":"Monitoring of the complement system status in patients with B-cell malignancies treated with rituximab","volume":"11","author":"Felberg","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.058_bib36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ekir.2024.04.058_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:14:31Z","timestamp":1719998071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924016930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2468024924016930"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.058","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Cell-Based Assay to Measure the Activity of the Complement Convertases","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}